Assertio (ASRT) to Release Quarterly Earnings on Monday

Assertio (NASDAQ:ASRT) is expected to be releasing its Q4 2025 results after the market closes on Monday, March 16th. Analysts expect Assertio to post earnings of ($3.05) per share and revenue of $6.1990 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 4:30 PM ET.

Assertio Price Performance

Shares of NASDAQ ASRT opened at $11.54 on Friday. The firm has a market capitalization of $74.11 million, a P/E ratio of -2.48 and a beta of 0.73. Assertio has a twelve month low of $7.65 and a twelve month high of $15.15. The company has a quick ratio of 1.43, a current ratio of 1.58 and a debt-to-equity ratio of 0.37. The stock’s 50-day simple moving average is $11.49 and its two-hundred day simple moving average is $11.77.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ASRT. Nantahala Capital Management LLC boosted its stake in shares of Assertio by 4.4% during the 2nd quarter. Nantahala Capital Management LLC now owns 8,810,073 shares of the company’s stock valued at $5,649,000 after purchasing an additional 370,311 shares in the last quarter. Vanguard Group Inc. raised its stake in Assertio by 0.9% in the third quarter. Vanguard Group Inc. now owns 4,425,543 shares of the company’s stock worth $3,899,000 after buying an additional 41,332 shares in the last quarter. Perritt Capital Management Inc raised its stake in Assertio by 51.6% in the third quarter. Perritt Capital Management Inc now owns 350,316 shares of the company’s stock worth $309,000 after buying an additional 119,281 shares in the last quarter. Opaleye Management Inc. purchased a new stake in Assertio in the fourth quarter worth about $2,585,000. Finally, Edgewood Management LLC purchased a new stake in Assertio in the fourth quarter worth about $975,000. 48.96% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ASRT. Zacks Research downgraded shares of Assertio from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Wall Street Zen raised Assertio to a “buy” rating in a research note on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Assertio in a report on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target (up from $3.00) on shares of Assertio in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $35.00.

About Assertio

Assertio Therapeutics, Inc, formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions.